HEALing Communities Study

Opioid Use Disorder (OUD) Clinical Trial

Official title:

HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04111939
• Other study ID #: 38088
• Secondary ID: 1UM1DA0493941UM1
• Status: Active, not recruiting
• Phase: N/A
• Start date: October 23, 2019
• Est. completion date: March 31, 2025

Study information

• Verified date: April 2024
• Source: RTI International
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will test the impact of implementing the Communities That Helping to End Addiction Long-term (HEAL) intervention on opioid overdose deaths within 67 highly affected communities with the goal of reducing opioid overdose deaths by 40%.

Description:

The HEALing Communities Study (HCS) is a multi-site, parallel group, cluster randomized wait-list controlled trial to test the impact of the Communities That HEAL (CTH) intervention, which is designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. The intervention will include 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder. Communities receiving the intervention will be engaged to reach individuals who are at highest risk of overdose death (e.g., out of treatment, leaving jail) and: (1) expand access to and receipt of medication for opioid use disorder (MOUD) and behavioral treatment, (2) increase the number of individuals retained in treatment beyond 6 months, (3) reduce the risk of fatal overdose through expansion of overdose education and naloxone distribution, and (4) improve prescription opioid safety. In addition, the study will determine (1) the factors that contribute to or impede successful implementation of the CTH intervention, (2) the factors that contribute to or impede sustainment of CTH intervention, and (3) the incremental costs and cost effectiveness of the CTH intervention.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 67
• Est. completion date: March 31, 2025
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• The community must be located in one of the four participating states: Kentucky, Ohio, Massachusetts, or New York.

• At least 30% of the communities selected within each state must be rural.

• Across all the HCS communities within each state, there must be a minimum of 150 opioid-related overdose fatalities (with at least 22 opioid-related overdose fatalities experienced by the rural communities) and a rate of at least 25 opioid-related overdose fatalities per 100,000 persons, based on 2016 data.

• The community must express willingness to address in their response strategy the implementation of MOUD, overdose prevention training, and naloxone distribution across their community.

• The community must express willingness to develop partnerships across health care, behavioral health, and justice settings for evidence-based practices to address opioid misuse, OUD, and overdoses.

Exclusion Criteria:

• Communities that did not meet the aforementioned inclusion criteria were excluded from the HCS.

Related Conditions & MeSH terms

• Opioid Use Disorder (OUD)
• Opioid-Related Disorders

Intervention

Other:
• Communities That HEAL
The Communities That HEAL (CTH) intervention is a community-engaged intervention designed to increase the adoption of an integrated set of evidence-based practices delivered across healthcare, behavioral health, justice, and other community-based settings. It includes 3 components: community engagement to assist key stakeholders in applying evidence-based practices to addressing their opioid crisis, a menu of evidence-based practices for communities to select and implement, and a communications campaign to build demand for evidence-based practices to address overdose and opioid use disorder.
• Wait-list control
Communities in the wait-list control condition will continue usual care during the first 30 months of the trial. At month 31, Wave 2 communities will begin receiving the CTH intervention.

Locations

Country	Name	City	State
United States	Boston Medical Center	Boston	Massachusetts
United States	Ohio State University	Columbus	Ohio
United States	University of Kentucky	Lexington	Kentucky
United States	Columbia University	New York	New York

Sponsors (7)

Lead Sponsor	Collaborator
RTI International	Boston Medical Center, Columbia University, National Institute on Drug Abuse (NIDA), Ohio State University, Substance Abuse and Mental Health Services Administration (SAMHSA), University of Kentucky

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of opioid overdose deaths	Count of HCS community resident overdose deaths (i.e. deaths with an underlying cause of drug poisoning) where opioids were determined to be contributing (alone or in combination with other drugs) to the drug poisoning.	Months 19-30
Secondary	Number of naloxone units distributed in communities	Count of naloxone units distributed in the HCS communities during the measurement period as captured by the following submeasures: 1) count of naloxone units distributed by the state health agency (secondary data from state health agencies) and HCS study logs for naloxone distributed by the study and 2) the count of naloxone units sold by pharmacies (IQVIA pharmacy data)	Months 19-30
Secondary	Number of individuals receiving buprenorphine products that are approved by the Food and Drug Administration (FDA) for treatment of OUD	Count of number of unique individuals receiving buprenorphine MOUD during the measurement period.	Months 19-30
Secondary	Incidents of high-risk opioid prescribing	Count of individuals with one or more of the following during the twelve month study period (months 19-30), and not in a prior specified time window (3 months): risk of continued opioid use (new opioid episode lasting at least 31 days); initiating opioid treatment with extended-release or long-acting opioid; incident high dosage (average = 90 mg morphine per day); and/or incident overlapping opioid and benzodiazepine for = 30 days.	Months 19-30